Cited by 362Lung Cancer Treatments and MutationsHER2/EGFR in Cancer ResearchCancer Genomics and Diagnostics

The DOI matches its Crossref record; 31 of the 32 references it cites were found in a registry or an index.

Natural History and Molecular Characteristics of Lung Cancers Harboring EGFR Exon 20 Insertions

Open access

Oxnard, Geoffrey R., Lo, Peter C., Nishino, Mizuki, Dahlberg, Suzanne E., Lindeman, Neal I., Butaney, Mohit, Jackman, David M., Johnson, Bruce E., Jänne, Pasi A.·2013·Journal of Thoracic Oncology

DOI 10.1097/jto.0b013e3182779d18PMC PMC3549533

Open this paper in CoChat — free account

Abstract

Introduction Exon 20 insertions are the third most common family of epidermal growth factor receptor (EGFR) mutations found in non-small-cell lung cancer (NSCLC). Little is known about cancers harboring these mutations aside from their lack of response to EGFR tyrosine kinase inhibitors, impairing the development of effective targeted therapies.Methods NSCLC patients with EGFR genotyping were studied using a mechanism approved by the Institutional Review Board. Cancers with exon 20 insertions were indentified, sequences were characterized, and effectiveness of different treatment regimens was reviewed retrospectively. Clinical characteristics and survival were compared with cancers harboring common EGFR mutations and cancers with wild-type EGFR.Results One thousand eighty-six patients underwent EGFR genotyping from 2004 to 2012. Twenty seven (2.5%) harbored exon 20 insertions, making up 9.2% of all cancers with documented EGFR mutations. Compared with wild-type cancers, those with exon 20 insertions were more commonly found in never-smokers and Asian patients. Insertion sequences were highly variable, with the most common variant (V769_D770insASV) making up only 22% of cases. Median survival of patients with exon 20 insertions was 16 months, similar to the survival of wild-type cancers and shorter than the survival of cancers with common EGFR mutations.Conclusions Patients with EGFR exon 20 insertions have similar clinical characteristics to those with common EGFR mutations but a poorer prognosis. The prevalence of this subset of NSCLC is similar to that of other genotype-defined subsets of lung adenocarcinoma (e.g. those with BRAF mutations, HER2 insertions, ROS1 rearrangements) and is a population of interest for trials of new targeted therapies.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1097/jto.0b013e3182779d18

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261 · cited 1×
“The identification of epidermal growth factor receptor (EGFR) mutations in a subset of non–small-cell lung cancer (NSCLC) and their association with durable responses to EGFR tyrosine kinase inhibitors (TKIs) has transformed our approach towards the use of targeted therapies in treating lung cancer.(1,2) This initial…”
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Kwak, E. L., Bang, Y., Camidge, D. R., Shaw, A. T., Solomon, B., Maki, R. G., Ou, S. I., Dezube, B. J., Janne, P. A., Costa, D. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006448 · Cited by 4,477
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Flaherty, K. T., Puzanov, I., Kim, K. B., Ribas, A., McArthur, G. A., Sosman, J. A., O'Dwyer, P. J., Lee, R. J., Grippo, J. F., Nolop, K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002011 · Cited by 3,103
Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers
Shigematsu, H., Lin, L., Takahashi, T., Nomura, M., Suzuki, M., Wistuba, I. I., Fong, K. M., Lee, H., Toyooka, S., Shimizu, N., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji055 · Cited by 2,377
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
Rosell, R., Moran, T., Queralt, C., Porta, R., Cardenal, F., Camps, C., Majem, M., Lopez-Vivanco, G., Isla, D., Provencio, M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904554 · Cited by 2,373
Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
Flaherty, K. T., Robert, C., Hersey, P., Nathan, P., Garbe, C., Milhem, M. M., Демидов, Л. В., Hassel, J. C., Rutkowski, P. L., Mohr, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203421 · Cited by 2,205
ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers
Bergethon, K., Shaw, A. T., Ignatius Ou, S.-H., Katayama, R., Lovly, C. M., McDonald, N. T., Massion, P. P., Siwak-Tapp, C., Gonzalez, A., Fang, R., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.6345 · Cited by 1,555
Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group
Flaherty, K. T., Robert, C., Hersey, P., Nathan, P., Garbe, C., Milhem, M. M., Демидов, Л. В., Hassel, J. C., Rutkowski, P. L., Mohr, P., et al. (2012) · Zurich Open Repository and Archive (University of Zurich) · doi:10.5167/uzh-63198 · Cited by 1,330
Mutations of the Epidermal Growth Factor Receptor Gene in Lung Cancer
Kosaka, T., Yatabe, Y., Endoh, H., Kuwano, H., Takahashi, T., & Mitsudomi, T. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2818 · Cited by 1,220

Flagged first, then by citations

Show all 32 references

1 of the 32 references couldn’t be matched to a known paper.

Sorted by citations

Items 101–200 of 362

Bispecific antibodies: unleashing a new era in oncology treatment
Shui, L., Wu, D., Yang, K., Sun, C., Li, Q., & Yin, R. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02390-y · Cited by 51
Conformational Landscapes of HER2 Exon 20 Insertions Explain Their Sensitivity to Kinase Inhibitors in Lung Adenocarcinoma
Zhao, S., Fang, W., Pan, H., Yang, Y., Liang, Y., Yang, L., Dong, X., Zhan, J., Wang, K., & Zhang, L. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.01.020 · Cited by 45
Non‐small cell lung cancer harboring a rare EGFR L747P mutation showing intrinsic resistance to both gefitinib and osimertinib (AZD9291): A case report
Huang, J., Wang, Y., Zhai, Y., & Wang, J. (2018) · Thoracic Cancer · doi:10.1111/1759-7714.12637 · Cited by 44
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-sensitive Exon 19 Insertion and Exon 20 Insertion in Patients With Advanced Non–Small-cell Lung Cancer
Lin, Y.-T., Liu, Y.-N., Wu, S.-G., Yang, J. C.-H., & Shih, J.-Y. (2017) · Clinical Lung Cancer · doi:10.1016/j.cllc.2016.12.014 · Cited by 43
Discovery of a Furanopyrimidine-Based Epidermal Growth Factor Receptor Inhibitor (DBPR112) as a Clinical Candidate for the Treatment of Non-Small Cell Lung Cancer
Lin, S., Hsu, Y. C., Peng, Y.-H., Ke, Y., Lin, W., Sun, H.-Y., Shiao, H., Kuo, F., Chen, P.-Y., Lien, T., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00722 · Cited by 44
Discovery of mobocertinib, a new irreversible tyrosine kinase inhibitor indicated for the treatment of non-small-cell lung cancer harboring EGFR exon 20 insertion mutations
Wang, J., Lam, D., Yang, J., & Hu, L. (2022) · Medicinal Chemistry Research · doi:10.1007/s00044-022-02952-5 · Cited by 43
Strategies to Overcome Bypass Mechanisms Mediating Clinical Resistance to EGFR Tyrosine Kinase Inhibition in Lung Cancer
Husain, H., Scur, M. D., Murtuza, A., Bui, N. Q., Woodward, B. D., & Kurzrock, R. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0105 · Cited by 44
EGFR exon 20 insertion mutations in non-small cell lung cancer
Wang, F., Li, C., Wu, Q., & Lu, H. (2020) · Translational Cancer Research · doi:10.21037/tcr.2020.03.10 · Cited by 40
Management of EGFR mutated nonsmall cell lung carcinoma patients
Grigoriu, B. D., Berghmans, T., & Meert, A. (2015) · European Respiratory Journal · doi:10.1183/09031936.00156614 · Cited by 41
Epidermal growth factor receptor exon 20 mutation in lung cancer: types, incidence, clinical features and impact on treatment
Noronha, V., Choughule, A. B., Patil, V., Joshi, A., Kumar, R., Philip, D. S. J., Banavali, S., Dutt, A., & Prabhash, K. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s133245 · Cited by 41
EGFR Exon 20 Insertion Mutations: Clinicopathological Characteristics and Treatment Outcomes in Advanced Non–Small Cell Lung Cancer
Leal, J. L., Alexander, M., Itchins, M., Wright, G. M., Kao, S., Hughes, B. G. M., Pavlakis, N., Clarke, S. J., Gill, A. J., Ainsworth, H., et al. (2021) · Clinical Lung Cancer · doi:10.1016/j.cllc.2021.04.009 · Cited by 41
Pemetrexed-based chemotherapy for non-small-cell lung cancer patients with EGFR exon 20 insertion mutation: a multicenter study
on behalf of AME Lung Cancer Collaborative Group, Xu, C., Wang, W., Wang, D., Wang, Q., Pu, X., Zhu, Y., Huang, J., Yu, Z., Cui, Z., et al. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-382 · Cited by 40
Clinicopathologic Characteristics, Treatment Outcomes, and Acquired Resistance Patterns of Atypical EGFR Mutations and HER2 Alterations in Stage IV Non–Small-Cell Lung Cancer
Patil, T., Mushtaq, R. R., Marsh, S. A., Azelby, C. M., Pujara, M., Davies, K. D., Aisner, D. L., Purcell, W. T., Schenk, E. L., Pacheco, J. M., et al. (2019) · Clinical Lung Cancer · doi:10.1016/j.cllc.2019.11.008 · Cited by 39
EGFR Exon 18 Mutations in East Asian Patients with Lung Adenocarcinomas: A Comprehensive Investigation of Prevalence, Clinicopathologic Characteristics and Prognosis
Cheng, C., Wang, R., Li, Y., Pan, Y., Zhang, Y., Li, H., Zheng, D., Zheng, S., Shen, X., Sun, Y., et al. (2015) · Scientific Reports · doi:10.1038/srep13959 · Cited by 38
Uncommon EGFR mutations in a cohort of Chinese NSCLC patients and outcomes of first-line EGFR-TKIs and platinum-based chemotherapy
Shi, J., Department of Medical Oncology, S. P. H. &. T. C. I., Yang, H., Jiang, T., Li, X., Zhao, C., Zhang, L., Zhao, S., Liu, X., Jia, Y., et al. (2017) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2017.06.09 · Cited by 37
Afatinib in the first-line treatment of patients with non-small cell lung cancer: clinical evidence and experience
Ricciuti, B., Baglivo, S., Giglio, A. D., & Chiari, R. (2018) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753466618808659 · Cited by 39
Non-small Cell Lung Cancer with EGFR or HER2 Exon 20 Insertion Mutations: Diagnosis and Treatment Options
Brazel, D., Kroening, G., & Nagasaka, M. (2022) · BioDrugs · doi:10.1007/s40259-022-00556-4 · Cited by 37
EGFR exon20 insertion mutations in non-small cell lung cancer: Clinical implications and recent advances in targeted therapies
Bai, Q., Wang, J., & Zhou, X. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102605 · Cited by 38
Prediction of sensitivity to gefitinib/erlotinib for EGFR mutations in NSCLC based on structural interaction fingerprints and multilinear principal component analysis
Zou, B., Lee, V. H.-F., & Yan, H. (2018) · BMC Bioinformatics · doi:10.1186/s12859-018-2093-6 · Cited by 37
Amivantamab compared with real-world therapies in patients with advanced non-small cell lung cancer harboring EGFR exon 20 insertion mutations who progressed after platinum-based chemotherapy
Minchom, A. R., Viteri, S., Bazhenova, L. A., Gadgeel, S. M., Ou, S. I., Trigo, J. M., Bauml, J. M., Backenroth, D., Bhattacharya, A., Li, T. M. W. Y., et al. (2022) · Lung Cancer · doi:10.1016/j.lungcan.2022.03.005 · Cited by 37
Non-small cell lung cancer with EGFR exon 20 insertion mutation: a systematic literature review and meta-analysis of patient outcomes
Kwon, C. S., Lin, H. M., Crossland, V., Churchill, E. N., Curran, E. J., Forsythe, A., Tomaras, D., & Ou, S. I. (2022) · Current Medical Research and Opinion · doi:10.1080/03007995.2022.2083326 · Cited by 39
Deep-Learning-Based Predictive Imaging Biomarker Model for EGFR Mutation Status in Non-Small Cell Lung Cancer from CT Imaging
Mahajan, A., Kania, V., Agarwal, U., Ashtekar, R. M., Shukla, S., Patil, V., Noronha, V., Joshi, A., Menon, N. S., Kumar, R., et al. (2024) · Cancers · doi:10.3390/cancers16061130 · Cited by 39
Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors
Chang, L.-C., Lim, C., Chang, L., Chen, K., Shih, J., & Yu, C. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.06.025 · Cited by 35
MET amplification increases the metastatic spread of EGFR-mutated NSCLC
Baldacci, S., Kherrouche, Z., Cockenpot, V., Stoven, L., Copin, M. C., Werkmeister, E., Marchand, N., Kyheng, M., Tulasne, D., & Cortot, A. B. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.09.008 · Cited by 34
The efficacy and possible mechanisms of immune checkpoint inhibitors in treating non‐small cell lung cancer patients with epidermal growth factor receptor mutation
Ma, L., Diao, B., Huang, Z., Wang, B., Yu, J., & Meng, X. (2021) · 癌症：英文版 · doi:10.1002/cac2.12229 · Cited by 33
An 8-gene signature for prediction of prognosis and chemoresponse in non-small cell lung cancer
Shahid, M., Choi, T. G., Nguyen, M. N., Matondo, A., Jo, Y. H., Yoo, J. Y., Nguyen, N. N. Y., Yun, H. R., Kim, J., Akter, S., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.13357 · Cited by 33
Next‐Generation Kinase Inhibitors Targeting Specific Biomarkers in Non‐Small Cell Lung Cancer (NSCLC): A Recent Overview
Das, D., Wang, J., & Hong, J. (2021) · ChemMedChem · doi:10.1002/cmdc.202100166 · Cited by 35
Epidermal growth factor receptor (EGFR) exon 20 mutations in non-small-cell lung cancer and resistance to EGFR-tyrosine kinase inhibitors
Woo, H. S., Ahn, H. K., Lee, H. Y., Park, I., Kim, Y. S., Hong, J., Sym, S. J., Park, J., Lee, J. H., Shin, D. B., et al. (2014) · Investigational New Drugs · doi:10.1007/s10637-014-0146-x · Cited by 32
Lung cancer in never-smokers. Does smoking history matter in the era of molecular diagnostics and targeted therapy?
Ou, S. I. (2013) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2012-201296 · Cited by 31
Discovery of a Highly Potent and Broadly Effective Epidermal Growth Factor Receptor and HER2 Exon 20 Insertion Mutant Inhibitor
Jang, J., Son, J., Park, E., Kosaka, T., Saxon, J. A., Clercq, D. J. H. D., Choi, H. G., Tanizaki, J., Eck, M. J., Janne, P. A., et al. (2018) · Angewandte Chemie International Edition · doi:10.1002/anie.201805187 · Cited by 32
Making NSCLC Crystal Clear: How Kinase Structures Revolutionized Lung Cancer Treatment
Vilachã, J. F., Mitchel, S. C., Akele, M. Z., Evans, S., & Groves, M. R. (2020) · Crystals · doi:10.3390/cryst10090725 · Cited by 29
Management of non-small cell lung cancer in the era of personalized medicine
Rocco, G., Morabito, A., Leone, A., Muto, P., Fiore, F., & Budillon, A. (2016) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2016.07.011 · Cited by 30
Biomarkers and targeted systemic therapies in advanced non-small cell lung cancer
Kumar, M., Ernani, V., & Owonikoko, T. K. (2015) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2015.06.009 · Cited by 31
Amivantamab for the treatment of EGFR exon 20 insertion mutant non-small cell lung cancer
Vyse, S., & Huang, P. H. (2021) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2022.2016397 · Cited by 33
Clinical characteristics of non-small cell lung cancer harboring mutations in exon 20 of EGFR or HER2
Takeda, M., Sakai, K., Hayashi, H., Tanaka, K., Tanizaki, J., Takahama, T., Haratani, K., Nishio, K., & Nakagawa, K. (2018) · Oncotarget · doi:10.18632/oncotarget.24958 · Cited by 29
Molecular charcterization of lung adenocarcinoma combining whole exome sequencing, copy number analysis and gene expression profiling
Testa, U., Pelosi, E., & Castelli, G. (2021) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2022.2017774 · Cited by 28
Consensus Recommendations to Optimize Testing for New Targetable Alterations in Non-Small Cell Lung Cancer
Ionescu, D. N., Stockley, T. L., Banerji, S. O., Couture, C., Mather, C. A., Xu, Z., Blais, N., Cheema, P. K., Chu, Q. S.-C., Melosky, B. L., et al. (2022) · Current Oncology · doi:10.3390/curroncol29070396 · Cited by 28
Prevalence, Clinicopathologic Characteristics, and Molecular Associations of EGFR Exon 20 Insertion Mutations in East Asian Patients with Lung Adenocarcinoma
Pan, Y., Zhang, Y., Li, Y., Hu, H., Wang, L., Li, H., Wang, R., Ye, T., Luo, X., Zhang, Y., et al. (2014) · Annals of Surgical Oncology · doi:10.1245/s10434-013-3452-1 · Cited by 28
Osimertinib for EGFR T790M mutation-positive non-small cell lung cancer
Soejima, K., Yasuda, H., & Hirano, T. (2016) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2017.1265446 · Cited by 31
Targeted Therapies for EGFR Exon 20 Insertion Mutation in Non-Small-Cell Lung Cancer
Seo, D., & Lim, J. H. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25115917 · Cited by 28
Identification of key differentially expressed genes associated with non‑small cell lung cancer by bioinformatics analyses
Xiao, Y., Feng, M., Ran, H., Han, X., & Li, X. (2018) · Molecular Medicine Reports · doi:10.3892/mmr.2018.8726 · Cited by 27
The effectiveness of afatinib in patients with lung adenocarcinoma harboring complex epidermal growth factor receptor mutation
Wu, S., Yu, C., Yang, J. C., & Shih, J. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920946156 · Cited by 27
Predicting EGFR mutation, ALK rearrangement, and uncommon EGFR mutation in NSCLC patients by driverless artificial intelligence: a cohort study
Tan, X., Li, Y., Wang, S., Xia, H., Meng, R., Xu, J., Duan, Y., Li, Y., Yang, G., Ma, Y., et al. (2022) · Respiratory Research · doi:10.1186/s12931-022-02053-2 · Cited by 30
Precision targeted therapy for EGFR mutation‐positive NSCLC : Dilemmas and coping strategies
Meng, Y., Bai, R., & Cui, J. (2023) · Thoracic Cancer · doi:10.1111/1759-7714.14858 · Cited by 28
Targeted Therapy for Non-Small Cell Lung Cancer
Noor, Z. S., Cummings, A. L., Johnson, M. M., Spiegel, M. L., & Goldman, J. W. (2020) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0039-1700994 · Cited by 27
Non-Small-Cell Lung Cancer: New Rare Targets—New Targeted Therapies—State of The Art and Future Directions
Stencel, K. M., Chmielewska, I., Milanowski, J., & Ramlau, R. (2021) · Cancers · doi:10.3390/cancers13081829 · Cited by 27
A study of therapy targeted EGFR/ALK mutations in Indian patients with lung adenocarcinoma: A clinical and epidemiological study
Rana, V., Ranjan, P., Jagani, R., Rathi, K. R., Kumar, D., & Khera, A. (2017) · Medical Journal Armed Forces India · doi:10.1016/j.mjafi.2017.09.005 · Cited by 25
Structural Basis for the Functional Changes by EGFR Exon 20 Insertion Mutations
Tamirat, M. Z., Kurppa, K. J., Elenius, K., & Johnson, M. S. (2021) · Cancers · doi:10.3390/cancers13051120 · Cited by 27
A Real-World Study of Patients with Advanced Non-squamous Non-small Cell Lung Cancer with EGFR Exon 20 Insertion: Clinical Characteristics and Outcomes
CHOUAID, C., Filleron, T., Debieuvre, D., Pérol, M., Girard, N., Dansin, É., Léna, H., Gervais, R., Cousin, S., Otto, J., et al. (2021) · Targeted Oncology · doi:10.1007/s11523-021-00848-9 · Cited by 25
Advances in the management of non-small-cell lung cancer harbouring EGFR exon 20 insertion mutations
Low, J. L., Lim, S. M., Lee, J. B., Cho, B. C., & Soo, R. A. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221146131 · Cited by 25
Tackling Drug Resistance in EGFR Exon 20 Insertion Mutant Lung Cancer
Pacini, L., Jenks, A. D., Vyse, S., Wilding, C. P., Arthur, A., & Huang, P. H. (2021) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s242045 · Cited by 27
Extensive functional evaluation of exon 20 insertion mutations of EGFR
Hirose, T., Ikegami, M., Endo, M., Matsumoto, Y., Nakashima, Y., Mano, H., & Kohsaka, S. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.12.023 · Cited by 23
Treatment Strategies for Non-Small Cell Lung Cancer Harboring Common and Uncommon EGFR Mutations: Drug Sensitivity Based on Exon Classification, and Structure-Function Analysis
Kitadai, R., & Okuma, Y. (2022) · Cancers · doi:10.3390/cancers14102519 · Cited by 24
Comparative Clinical Outcomes Between EGFR Ex20ins and Wildtype NSCLC Treated with Immune Checkpoint Inhibitors
Girard, N., Minchom, A. R., Ou, S. I., Gadgeel, S. M., Trigo, J. M., Viteri, S., Bauml, J. M., Londhe, A., Mahadevia, P. J., & Bazhenova, L. A. (2022) · Clinical Lung Cancer · doi:10.1016/j.cllc.2022.07.007 · Cited by 22
A real-world study of the efficacy and safety of furmonertinib for patients with non-small cell lung cancer with EGFR exon 20 insertion mutations
Sa, H., Shi, Y., Ding, C., & Ma, K. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-04726-x · Cited by 21
A Potent Derivative of Indolizino[6,7-b]Indole for Treatment of Human Non–Small Cell Lung Cancer Cells
Chen, C., Wu, M.-H., Chen, Y., Yen, T.-Y., Lin, Y., Chao, S.-H., Tala, S. D., Tsai, T., Su, T., & Lee, T. (2016) · Neoplasia · doi:10.1016/j.neo.2016.02.005 · Cited by 22
Exploring 4th generation EGFR inhibitors: A review of clinical outcomes and structural binding insights
Tariq, A., Shoaib, M., Qu, L., Shoukat, S., Nan, X., & Song, J. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177608 · Cited by 22
Spotlight on Amivantamab (JNJ-61186372) for EGFR Exon 20 Insertions Positive Non-Small Cell Lung Cancer
Brazel, D., & Nagasaka, M. (2021) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s337861 · Cited by 22
Potential mechanism of primary resistance to icotinib in patients with advanced non–small cell lung cancer harboring uncommon mutant epidermal growth factor receptor: A multi‐center study
Lei, L., Wang, W., Zhu, Y., Li, J., Fang, Y., Wang, H., Zhuang, W., Zhang, Y.-B., Wang, L., Fang, M., et al. (2019) · Cancer Science · doi:10.1111/cas.14277 · Cited by 20
EGFR Exon 20 Insertion Mutations in Sinonasal Squamous Cell Carcinoma
Pacini, L., Cabal, V. N., Hermsen, M. A. J. A., & Huang, P. H. (2022) · Cancers · doi:10.3390/cancers14020394 · Cited by 21
Mobocertinib: Mechanism of action, clinical, and translational science
Hanley, M. J., Camidge, D. R., Fram, R. J., & Gupta, N. (2024) · Clinical and Translational Science · doi:10.1111/cts.13766 · Cited by 20
Case Report: Afatinib Treatment in a Patient With NSCLC Harboring a Rare EGFR Exon 20 Mutation
Zöchbauer‐Müller, S., Kaserer, B., Prosch, H., Cseh, A., Solca, F., Bauer, M. J., & Müllauer, L. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.593852 · Cited by 20
An Adjusted Treatment Comparison Comparing Amivantamab Versus Real-World Clinical Practice in Europe and the United States for Patients with Advanced Non-Small Cell Lung Cancer with Activating Epidermal Growth Factor Receptor Exon 20 Insertion Mutations
CHOUAID, C., Bosquet, L., Girard, N., Kron, A., Scheffler, M., Griesinger, F., Sebastian, M., Trigo, J. M., Arias, C. S. V., Knott, C. S., et al. (2023) · Advances in Therapy · doi:10.1007/s12325-022-02408-7 · Cited by 18
Single‐Dose Pharmacokinetics and Tolerability of the Oral Epidermal Growth Factor Receptor Inhibitor Mobocertinib (TAK‐788) in Healthy Volunteers: Low‐Fat Meal Effect and Relative Bioavailability of 2 Capsule Products
Zhang, S., Jin, S., Griffin, C., Feng, Z., Lin, J., Baratta, M., Brake, R. L., Venkatakrishnan, K., & Gupta, N. (2021) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.951 · Cited by 18
EGFR Exon 20 Insertion in Metastatic Non-Small-Cell Lung Cancer: Survival and Clinical Efficacy of EGFR Tyrosine-Kinase Inhibitor and Chemotherapy
Chelabi, S., Mignard, X., Leroy, K., Monnet, I., Brosseau, S., Théou–Anton, N., Massiani, M.-A., Friard, S., Duchemann, B., Fabre, E., et al. (2021) · Cancers · doi:10.3390/cancers13205132 · Cited by 18
Immunotherapy for non-small cell lung cancer with EGFR or HER2 exon 20 insertion mutations: a real-world analysis
Zhang, M., Huang, Q., Yu, M., Xue, J., Huang, M., Lu, Y., & Zhang, Y. (2023) · Translational Lung Cancer Research · doi:10.21037/tlcr-23-167 · Cited by 18
A comprehensive overview of the heterogeneity of EGFR exon 20 variants in NSCLC and (pre)clinical activity to currently available treatments
Zwierenga, F., van Veggel, B. A. M. H., van den Berg, A., Groen, H. J. M., Zhang, L., Groves, M. R., Kok, K., Smit, E. F., Hiltermann, T. J. N., Langen, A. J. D., et al. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102628 · Cited by 17
Current status and breakthroughs in treating advanced non-small cell lung cancer with EGFR exon 20 insertion mutations
Hu, M., Zhong, C., Wang, J., Chen, J., & Zhou, T. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1399975 · Cited by 17
Emerging uses of biomarkers in lung cancer management: molecular mechanisms of resistance
Attarian, S., Rahman, N., & Halmos, B. (2017) · Annals of Translational Medicine · doi:10.21037/atm.2017.07.18 · Cited by 17
Optimizing diagnosis and treatment of EGFR exon 20 insertions mutant NSCLC
Passiglia, F., Malapelle, U., Normanno, N., & Pinto, C. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102438 · Cited by 16
The development of amivantamab for the treatment of non-small cell lung cancer
Brazel, D., & Nagasaka, M. (2023) · Respiratory Research · doi:10.1186/s12931-023-02558-4 · Cited by 19
Comparison of next generation sequencing, SNaPshot assay and real-time polymerase chain reaction for lung adenocarcinoma EGFR mutation assessment
Cernomaz, A. T., Macovei, I. I., Pavel, I., Grigoriu, C., Marinca, M. V., Baty, F., Péter, S., Zonda, R., Brutsche, M. H., & Grigoriu, B. D. (2016) · BMC Pulmonary Medicine · doi:10.1186/s12890-016-0250-0 · Cited by 16
A Structural Insight Into Two Important ErbB Receptors (EGFR and HER2) and Their Relevance to Non‐Small Cell Lung Cancer
Topalan, E., Büyükgüngör, A., Çiğdem, M., Gura, S. F., Sever, B., Otsuka, M., Fujita, M., DeMirci, H., & Ciftci, H. I. (2025) · Archiv der Pharmazie · doi:10.1002/ardp.202400992 · Cited by 18
From Rarity to Reality: Osimertinib’s Promising Horizon in Treating Uncommon EGFR Mutations in Non–Small Cell Lung Cancer
Fukuda, A., & Okuma, Y. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-4035 · Cited by 16
Successful treatment of a lung adenocarcinoma patient with a novel EGFR exon 20-ins mutation with afatinib
Cai, Y., Wang, X., Guo, Y., Sun, C., Xu, Y., Qiu, S., & Ma, K. (2019) · Medicine · doi:10.1097/md.0000000000013890 · Cited by 15
Tumor genomics and response to chemotherapy in advanced non-small cell lung cancer with exon 20 insertion epidermal growth factor receptor mutations
Wang, Y., Li, J., Zhou, Y., Cao, S., Ling, X., Zhang, Y., Nie, W., & Zhong, H. (2020) · Annals of Translational Medicine · doi:10.21037/atm-20-6172 · Cited by 14
Structural Mechanism and Inhibitors Targeting EGFR Exon 20 Insertion (Ex20ins) Mutations
Chen, H., Hu, S., Patterson, A. V., Smaill, J. B., Ding, K., & Lu, X. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00875 · Cited by 14
NCCN Guidelines Version 1.2015 Panel Members Non-Small Cell Lung Cancer
Ettinger, D. S., Kimmel, S., Wood, D. E., Akerley, W., Bazhenova, L. A., Borghaei, H., Camidge, D. R., Cheney, R. T., Chirieac, L. R., Jahan, T. M., et al. (2014) · Cited by 14
Real-world clinical treatment outcomes in Chinese non-small cell lung cancer with EGFR exon 20 insertion mutations
Shi, C., Xing, R., Li, M., Feng, J., Sun, R., Wei, B., Guo, Y., Ma, J., & Wang, H. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.949304 · Cited by 16
First‐line immunotherapy or angiogenesis inhibitor combined with chemotherapy for advanced non‐small cell lung cancer with EGFR exon 20 insertions: Real‐world evidence from China
Yang, G., Yang, Y., Liu, R., Li, W., Xu, H., Hao, X., Li, J., Zhang, S., Xu, F., Lei, S., et al. (2022) · Cancer Medicine · doi:10.1002/cam4.4852 · Cited by 13
Multidisciplinary expert consensus on diagnosis and treatment of multiple lung cancers
Chen, K., Liu, A., Wang, C., Hu, C., Chen, C., Yang, F., Chen, H., Shen, H., Zhang, H., Liu, H., et al. (2025) · Med · doi:10.1016/j.medj.2025.100643 · Cited by 14
Clinical implementation of plasma EGFR T790M testing using droplet digital PCR in TKI-resistant NSCLC patients
Chan, D. L. H., Toh, G. L.-X., & Goh, L. L. (2020) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2020.104515 · Cited by 13
Real‐world clinical analysis in 190 advanced NSCLC patients with uncommon EGFR mutations: A multi‐center study
Qin, Y., Long, Y., Tang, Y., Tian, Y., Li, J., Duan, P., Luo, J., Yu, M., Li, Y., Zhou, X., et al. (2023) · Cancer Science · doi:10.1111/cas.15769 · Cited by 12
Epidermal growth factor receptor exon 20 insertion variants in non-small cell lung cancer patients
Malapelle, U., Pilotto, S., Reale, M. L., Passiglia, F., Pisapia, P., Pepe, F., Belluomini, L., Galetta, D., Cortinovis, D. L., Tiseo, M., et al. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103536 · Cited by 13
Non-small cell lung cancer: an update on emerging EGFR-targeted therapies
Favorito, V., Ricciotti, I., Giglio, A. D., Fabbri, L., Seminerio, R., Federico, A. D., Gariazzo, E., Costabile, S., & Metro, G. (2024) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2024.2331139 · Cited by 13
The EGFR C797S Mutation Confers Resistance to a Novel EGFR Inhibitor CLN-081 to EGFR Exon 20 Insertion Mutations
Kagawa, Y., Hayashida, T., Liu, J., Mori, S., Izumi, H., Kumagai, S., Udagawa, H., Hattori, N., Goto, K., & Kobayashi, S. S. (2023) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2023.100462 · Cited by 12
Comprehensive profiling of EGFR mutation subtypes reveals genomic-clinical associations in non-small-cell lung cancer patients on first-generation EGFR inhibitors
Bai, Y., Liu, X., Zheng, L., Wang, S., Zhang, J., Xiong, S., Zhang, P., Jiao, Z., Zhao, G., Zhou, C., et al. (2023) · Neoplasia · doi:10.1016/j.neo.2023.100888 · Cited by 12
EGFR mutation specific immunohistochemistry is a useful adjunct which helps to identify false negative mutation testing in lung cancer
Houang, M., Sioson, L., Clarkson, A., Watson, N., Farzin, M., Toon, C. W., Raut, A., O'Toole, S. A., Cooper, W. A., Pavlakis, N., et al. (2014) · Pathology · doi:10.1097/pat.0000000000000141 · Cited by 12
Clinicoradiological features associated with epidermal growth factor receptor exon 19 and 21 mutation in lung adenocarcinoma
Zhao, F., Zhao, Y., Han, L. Z., Xie, Y. S., Liu, Y., & Ye, Z. (2018) · Clinical Radiology · doi:10.1016/j.crad.2018.10.001 · Cited by 12
Audit of Molecular Mechanisms of Primary and Secondary Resistance to Various Generations of Tyrosine Kinase Inhibitors in Known Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Cancer Patients in a Tertiary Centre
Suryavanshi, M., Jaipuria, J., Mattoo, S., Dhandha, S., & Khatri, M. (2022) · Clinical Oncology · doi:10.1016/j.clon.2022.06.003 · Cited by 13
Amivantamab in the Treatment of Metastatic NSCLC: Patient Selection and Special Considerations
Petrini, I., & Giaccone, G. (2022) · OncoTargets and Therapy · doi:10.2147/ott.s329095 · Cited by 14
Amivantamab Plus Lazertinib in Atypical EGFR -Mutated Advanced Non–Small Cell Lung Cancer: Results From CHRYSALIS-2
Tomasini, P., Wang, Y., Li, Y., Felip, E., Wu, L., Cui, J., Besse, B., Spira, A. I., Neal, J. W., Goto, K., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-24-02835 · Cited by 13
Clinical outcomes in patients with non-small cell lung cancer harboring EGFR Exon20 in-frame insertions in the near-loop and far-loop: Results from LC-SCRUM-Asia
Okahisa, M., Udagawa, H., Matsumoto, S., Kato, T., Yokouchi, H., Furuya, N., Kanemaru, R., Toyozawa, R., Nishiyama, A., Ohashi, K., et al. (2024) · Lung Cancer · doi:10.1016/j.lungcan.2024.107798 · Cited by 12
Population pharmacokinetics of mobocertinib in healthy volunteers and patients with non–small cell lung cancer
Gupta, N., Pierrillas, P. B., Hanley, M. J., Zhang, S., & Diderichsen, P. M. (2022) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12785 · Cited by 11
Exploring the spatiotemporal genetic heterogeneity in metastatic lung adenocarcinoma using a nuclei flow‐sorting approach
Lorber, T., Andor, N., Dietsche, T., Perrina, V., Juškevičius, D., Pereira, K., Greer, S., Krause, A., Müller, D. C., Prince, S. S., et al. (2018) · The Journal of Pathology · doi:10.1002/path.5183 · Cited by 11
Effects of KMT2D mutation and its exon 39 mutation on the immune microenvironment and drug sensitivity in colorectal adenocarcinoma
Liu, C., Jin, Y., Zhang, H., Yan, J., Guo, Y., Bao, X., & Zhao, P. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e13629 · Cited by 11
Persist or resist: Immune checkpoint inhibitors in EGFR ‐mutated NSCLC
Zhu, P., Li, Z., Sun, Y., Liu, T., & Yin, R. H. (2024) · Cancer Science · doi:10.1111/cas.16428 · Cited by 10
Amivantamab: TreatingEGFRExon 20–Mutant Cancers With Bispecific Antibody-Mediated Receptor Degradation
Köhler, J., & Janne, P. A. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.01494 · Cited by 11
Diagnostic-Therapeutic Pathway and Outcomes of Early Stage NSCLC: a Focus on EGFR Testing in the Real-World
Pasello, G., Lorenzi, M., Pretelli, G., Comacchio, G. M., Pezzuto, F., Schiavon, M., Buja, A., Frega, S., Bonanno, L., Guarneri, V., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.909064 · Cited by 10
EGFR and ERBB2 exon 20 insertion/duplication in advanced non–small cell lung cancer: genomic profiling and clinicopathologic features
Sompallae, R. R., Dundar, B., Guseva, N. V., Bossler, A., & Ma, D. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1163485 · Cited by 10

Authors: Oxnard, G. R., Lo, P. C., Nishino, M., Dahlberg, S. E., Lindeman, N. I., Butaney, M., Jackman, D. M., Johnson, B. E., & Jänne, P. A.
Affiliations: Brigham and Women's Hospital (US)
Dana-Farber Cancer Institute (US)
Corresponding author: Oxnard, Geoffrey R.
ORCID: Oxnard, Geoffrey R.
Nishino, Mizuki
Dahlberg, Suzanne E.
Lindeman, Neal I.
Butaney, Mohit
Johnson, Bruce E.
Venue: Journal of Thoracic Oncology
Publisher: Elsevier BV
Published: 2013-02
Volume: 8
Issue: 2
Pages: 179-184
ISSN: 1556-0864 (ISSN-L)
DOI: 10.1097/jto.0b013e3182779d18
PMC: PMC3549533
OpenAlex: W2075445339
Cited by: 360
References: 32
Citations by year: 2026: 17 · 2025: 30 · 2024: 33 · 2023: 41 · 2022: 50 · 2021: 36 · 2020: 31 · 2019: 26 · 2018: 24 · 2017: 19 · 2016: 16 · 2015: 15 · 2014: 15 · 2013: 7
FWCI: 14.35
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 1034 d)
Locations: Journal of Thoracic Oncology (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: National Institutes of Health (5k23ca157631-02)
National Cancer Institute (K23-CA157631, P50CA090578, R01CA135257)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Keywords: EGFR exon 20 insertion, non-small cell lung cancer, lung adenocarcinoma, EGFR mutation, EGFR tyrosine kinase inhibitors, survival, never smokers, Asian patients, targeted therapy, molecular properties
MeSH terms: Adult, Aged, Aged, 80 and over, Amino Acid Sequence, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Exons, Female, Follow-Up Studies, Humans, Lung Neoplasms, Male, Middle Aged, Molecular Sequence Data, Mutation, Neoplasm Staging, Prognosis, Retrospective Studies, Survival Rate, Mutagenesis, Insertional, Sequence Homology, Amino Acid, Young Adult, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Natural History and Molecular Characteristics of Lung Cancers Harboring EGFR Exon 20 Insertions

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks